These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

737 related items for PubMed ID: 1710526

  • 1. Octimibate, a potent non-prostanoid inhibitor of platelet aggregation, acts via the prostacyclin receptor.
    Merritt JE, Hallam TJ, Brown AM, Boyfield I, Cooper DG, Hickey DM, Jaxa-Chamiec AA, Kaumann AJ, Keen M, Kelly E.
    Br J Pharmacol; 1991 Jan; 102(1):251-9. PubMed ID: 1710526
    [Abstract] [Full Text] [Related]

  • 2. Primate vascular responses to octimibate, a non-prostanoid agonist at the prostacyclin receptor.
    Merritt JE, Brown AM, Bund S, Cooper DG, Egan JW, Hallam TJ, Heagerty AM, Hickey DM, Kaumann AJ, Keen M.
    Br J Pharmacol; 1991 Jan; 102(1):260-6. PubMed ID: 2043927
    [Abstract] [Full Text] [Related]

  • 3. Octimibate inhibition of platelet aggregation: stimulation of adenylate cyclase through prostacyclin receptor activation.
    Seiler S, Brassard CL, Arnold AJ, Meanwell NA, Fleming JS, Keely SL.
    J Pharmacol Exp Ther; 1990 Dec; 255(3):1021-6. PubMed ID: 2175792
    [Abstract] [Full Text] [Related]

  • 4. Functional and ligand binding studies suggest heterogeneity of platelet prostacyclin receptors.
    Armstrong RA, Lawrence RA, Jones RL, Wilson NH, Collier A.
    Br J Pharmacol; 1989 Jul; 97(3):657-68. PubMed ID: 2474350
    [Abstract] [Full Text] [Related]

  • 5. [3-[4-(4,5-Diphenyl-2-oxazolyl)-5-oxazolyl]phenoxy]acetic acid (BMY 45778) is a potent non-prostanoid prostacyclin partial agonist: effects on platelet aggregation, adenylyl cyclase, cAMP levels, protein kinase, and iloprost binding.
    Seiler SM, Brassard CL, Federici ME, Romine J, Meanwell NA.
    Prostaglandins; 1997 Jan; 53(1):21-35. PubMed ID: 9068064
    [Abstract] [Full Text] [Related]

  • 6. Prostacyclin receptor-independent inhibition of phospholipase C activity by non-prostanoid prostacyclin mimetics.
    Chow KB, Wong YH, Wise H.
    Br J Pharmacol; 2001 Dec; 134(7):1375-84. PubMed ID: 11724742
    [Abstract] [Full Text] [Related]

  • 7. Synergistic interaction of adenylate cyclase activators and nitric oxide donor SIN-1 on platelet cyclic AMP.
    Fisch A, Michael-Hepp J, Meyer J, Darius H.
    Eur J Pharmacol; 1995 May 26; 289(3):455-61. PubMed ID: 7556414
    [Abstract] [Full Text] [Related]

  • 8. 2-[3-[2-(4,5-Diphenyl-2-oxazolyl) ethyl] phenoxy] acetic acid (BMY 42393): a new, structurally-novel prostacyclin partial agonist: 1). Inhibition of platelet aggregation and mechanism of action.
    Seiler SM, Brassard CL, Federici ME, Buchanan JO, Zavoico GB, Fleming JS, Meanwell NA.
    Thromb Res; 1994 Apr 15; 74(2):115-23. PubMed ID: 8029812
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. SQ-27986 inhibition of platelet aggregation is mediated through activation of platelet prostaglandin D2 receptors.
    Seiler S, Brassard CL, Federici ME.
    Prostaglandins; 1990 Aug 15; 40(2):119-30. PubMed ID: 2171039
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of human platelets and polymorphonuclear neutrophils by the potent and metabolically stable prostaglandin D2 analog ZK 118.182.
    Darius H, Michael-Hepp J, Thierauch KH, Fisch A.
    Eur J Pharmacol; 1994 Jun 13; 258(3):207-13. PubMed ID: 7522176
    [Abstract] [Full Text] [Related]

  • 12. Structure-activity relationships associated with 3,4,5-triphenyl-1H-pyrazole-1-nonanoic acid, a nonprostanoid prostacyclin mimetic.
    Meanwell NA, Rosenfeld MJ, Wright JJ, Brassard CL, Buchanan JO, Federici ME, Fleming JS, Seiler SM.
    J Med Chem; 1992 Jan 24; 35(2):389-97. PubMed ID: 1370696
    [Abstract] [Full Text] [Related]

  • 13. Competitive antagonism at thromboxane receptors in human platelets.
    Armstrong RA, Jones RL, Peesapati V, Will SG, Wilson NH.
    Br J Pharmacol; 1985 Mar 24; 84(3):595-607. PubMed ID: 2580580
    [Abstract] [Full Text] [Related]

  • 14. Prostacyclin receptor desensitization is a reversible phenomenon in human platelets.
    Fisch A, Tobusch K, Veit K, Meyer J, Darius H.
    Circulation; 1997 Aug 05; 96(3):756-60. PubMed ID: 9264479
    [Abstract] [Full Text] [Related]

  • 15. Synergistic platelet inhibitory effect of the phosphodiesterase inhibitor piroximone and iloprost.
    Buerke M, Dieterich HA, Meyer J, Darius H.
    Agents Actions Suppl; 1992 Aug 05; 37():71-7. PubMed ID: 1378692
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Inhibition of adenylate cyclase by adenosine analogues in preparations of broken and intact human platelets. Evidence for the unidirectional control of platelet function by cyclic AMP.
    Haslam RJ, Davidson MM, Desjardins JV.
    Biochem J; 1978 Oct 15; 176(1):83-95. PubMed ID: 215136
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The inhibitory effects of non-prostanoid prostacyclin mimetics on rat neutrophil function.
    Wise H.
    Prostaglandins Leukot Essent Fatty Acids; 1996 May 15; 54(5):351-60. PubMed ID: 8832764
    [Abstract] [Full Text] [Related]

  • 20. Effects of heparin on prostacyclin binding and platelet adenylate cyclase activity stimulated by iloprost and forskolin.
    Jaschonek K, Faul C, Daiss W, Weisenberger H.
    Prostaglandins Leukot Med; 1986 Oct 15; 24(2-3):199-206. PubMed ID: 2432618
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.